Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Optimizing Care Transitions in Multiple Myeloma: Bridging Academic and Community Practices for Bispecific Antibody Therapy : Episode 7

Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care

October 25, 2024
By Cesar Rodriguez Valdes, MD
Binod Dhakal, MD, MS
  • Appalanaidu Sasapu MD, FACP
  • Leo Shunyakov, MD

Opinion
Video

Panelists discuss how transitioning patients with multiple myeloma from community to academic settings faces challenges including communication gaps, differences in treatment approaches, patient reluctance, and logistical hurdles.

EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration

EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma

EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?

EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care

EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center

EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care

Now Viewing

EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care

EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled

EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies

EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients

EP: 11.Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma

EP: 12.Protocols for Monitoring and Managing Long-Term Complications of Bispecific Therapy in Mutlplie Myeloma

EP: 13.Enhancing Communication Between Academic and Community Oncologists During Referral and Treatment in Multiple Myeloma.

EP: 14.Optimizing Patient Reintegration into Community Care Post-Academic Treatment of Bispecifics in Multiple Myeloma

EP: 15.Unmet Needs and Future Directions for Enhancing Bispecific Therapy Care Transitions in Multiple Myeloma

Video content above is prompted by the following:

  • What are some challenges you are seeing when transitioning from community to academic settings
Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
4 experts in this video
4 experts in this video
Related Content
Advertisement

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma

Russ Conroy
June 24th 2025
Article

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Related Content
Advertisement

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma

Russ Conroy
June 24th 2025
Article

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.


1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
April 15th 2025
Podcast

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.


Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.


1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
April 15th 2025
Podcast

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.


Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.


Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.